ERBB2 and breast carcinoma: Moving into clinical development, phase-II clinical trials for HER2+ primary breast cancers have been conducted to evaluate the addition of buparlisib to paclitaxel and trastuzumab (a monoclonal antibody that targets HER2) treatment [252].